SEI Investments’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $322K | Sell |
4,471
-5,821
| -57% | -$331K | ﹤0.01% | 2802 |
|
|
2025
Q4 | $435K | Sell |
10,292
-3,452
| -25% | -$193K | ﹤0.01% | 2571 |
|
|
2025
Q3 | $782K | Buy |
+13,744
| New | +$455K | ﹤0.01% | 2068 |
|
|
2025
Q2 | – | Sell |
-6,277
| Closed | -$64K | – | 2875 |
|
|
2025
Q1 | $64K | Hold |
6,277
| – | – | ﹤0.01% | 2659 |
|
|
2024
Q4 | $87.6K | Buy |
6,277
+2,110
| +51% | +$37.2K | ﹤0.01% | 2604 |
|
|
2024
Q3 | $81.2K | Buy |
+4,167
| New | +$79.4K | ﹤0.01% | 2585 |
|
|
2024
Q2 | – | Sell |
-1,533
| Closed | -$21.5K | – | 2706 |
|
|
2024
Q1 | $21.5K | Hold |
1,533
| – | – | ﹤0.01% | 2598 |
|
|
2023
Q4 | $13K | Sell |
1,533
-1
| -0.1% | -$8 | ﹤0.01% | 2599 |
|
|
2023
Q3 | $13.7K | Hold |
1,534
| – | – | ﹤0.01% | 2612 |
|
|
2023
Q2 | $13.2K | Sell |
1,534
-296
| -16% | -$3.16K | ﹤0.01% | 2664 |
|
|
2023
Q1 | $19.3K | Buy |
1,830
+296
| +19% | +$8.96K | ﹤0.01% | 2662 |
|
|
2022
Q4 | $52K | Buy |
1,534
+333
| +28% | +$16.1K | ﹤0.01% | 2486 |
|
|
2022
Q3 | $58K | Hold |
1,201
| – | – | ﹤0.01% | 2616 |
|
|
2022
Q2 | $68K | Hold |
1,201
| – | – | ﹤0.01% | 2590 |
|
|
2022
Q1 | $97K | Hold |
1,201
| – | – | ﹤0.01% | 2512 |
|
|
2021
Q4 | $243K | Sell |
1,201
-2
| -0.2% | -$434 | ﹤0.01% | 2407 |
|
|
2021
Q3 | $323K | Sell |
1,203
-408
| -25% | -$98.1K | ﹤0.01% | 2281 |
|
|
2021
Q2 | $410K | Hold |
1,611
| – | – | ﹤0.01% | 2191 |
|
|
2021
Q1 | $477K | Sell |
1,611
-79
| -5% | -$24.6K | ﹤0.01% | 2052 |
|
|
2020
Q4 | $427K | Buy |
1,690
+16
| +1% | +$4.13K | ﹤0.01% | 2063 |
|
|
2020
Q3 | $415K | Buy |
1,674
+288
| +21% | +$90.6K | ﹤0.01% | 1962 |
|
|
2020
Q2 | $480K | Buy |
1,386
+136
| +11% | +$42.4K | ﹤0.01% | 1868 |
|
|
2020
Q1 | $332K | Buy |
1,250
+110
| +10% | +$34K | ﹤0.01% | 1880 |
|
|
2019
Q4 | $368K | Buy |
+1,140
| New | +$331K | ﹤0.01% | 2058 |
|
|
2019
Q3 | – | Sell |
-480
| Closed | -$259K | – | 2412 |
|
|
2019
Q2 | $259K | Buy |
480
+42
| +10% | +$21.1K | ﹤0.01% | 2161 |
|
|
2019
Q1 | $224K | Sell |
438
-3,296
| -88% | -$1.95M | ﹤0.01% | 2236 |
|
|
2018
Q4 | $2.81M | Buy |
3,734
+1,439
| +63% | +$869K | 0.01% | 1167 |
|
|
2018
Q3 | $2.1M | Sell |
2,295
-1,934
| -46% | -$1.65M | 0.01% | 1246 |
|
|
2018
Q2 | $3.1M | Sell |
4,229
-2,253
| -35% | -$2.6M | 0.01% | 1140 |
|
|
2018
Q1 | $10.3M | Sell |
6,482
-1,549
| -19% | -$2M | 0.04% | 501 |
|
|
2017
Q4 | $7.19M | Sell |
8,031
-7,858
| -49% | -$4.65M | 0.03% | 745 |
|
|
2017
Q3 | $5.72M | Sell |
15,889
-5,401
| -25% | -$1.69M | 0.02% | 829 |
|
|
2017
Q2 | $6.24M | Buy |
21,290
+7,412
| +53% | +$2.14M | 0.02% | 742 |
|
|
2017
Q1 | $4.89M | Sell |
13,878
-3,044
| -18% | -$684K | 0.02% | 803 |
|
|
2016
Q4 | $3.11M | Buy |
16,922
+16,447
| +3,463% | +$3.34M | 0.02% | 974 |
|
|
2016
Q3 | $122K | Sell |
475
-3,359
| -88% | -$865K | ﹤0.01% | 1824 |
|
|
2016
Q2 | $818K | Buy |
3,834
+940
| +32% | +$210K | ﹤0.01% | 1222 |
|
|
2016
Q1 | $597K | Sell |
2,894
-172
| -6% | -$33K | ﹤0.01% | 1260 |
|
|
2015
Q4 | $775K | Sell |
3,066
-3,993
| -57% | -$821K | ﹤0.01% | 1259 |
|
|
2015
Q3 | $1.16M | Buy |
7,059
+3,993
| +130% | +$706K | 0.01% | 1002 |
|
|
2015
Q2 | $575K | Hold |
3,066
| – | – | 0.01% | 1147 |
|
|
2015
Q1 | $506K | Buy |
+3,066
| New | +$630K | ﹤0.01% | 1178 |
|
Other funds holding NKTR
BI
TSC
VCM
PM
AC
SEI Investments's NKTR Position: Q1 2026 in Review
SEI Investments reduced its Nektar Therapeutics (NKTR) stake by 57% in Q1 2026, selling an estimated $331K and leaving 4,471 shares worth $322K. The position accounts for ﹤0.01% of the portfolio, ranked #2802.
SEI Investments first reported a position in NKTR in Q1 2015 and has held it in 42 quarters since. The position peaked at $10.3M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.
- SEI Investments held 4,471 shares of Nektar Therapeutics worth $322K as of Q1 2026.
- SEI Investments sold 5,821 Nektar Therapeutics shares in Q1 2026, an estimated $331K.
- Nektar Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q1 2026, its #2802 holding.
- SEI Investments first reported a position in Nektar Therapeutics in Q1 2015 and has held it in 42 quarters since.
- SEI Investments's Nektar Therapeutics position peaked at $10.3M in Q1 2018.
- 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.
Based on SEI Investments's 13F filing for Q1 2026, filed 13 May 2026.